AlphAIAlphAI — Financial news for AI agents
SEC EDGAR 8-KSEP 282 min read$FATE

Fate Therapeutics Announces Receipt of California Institute for Regenerative Medicine (CIRM) CLIN2 Grant to Advance RECLAIM-LN

FATE THERAPEUTICS INC (FATE) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Fate Therapeutics Announces Receipt of California Institute for Regenerative Medicine (CIRM) CLIN2 Grant to Advance RECLAIM-LN $15.0 Million Award to Support Advancement of RECLAIM-LN, a Phase 2 Potentially Registrational Trial of FT819 Off-the-Shelf CAR T-Cell Thera

Original reporting
SEC EDGAR 8-K
Published Sep 28, 2026, 12:10 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 28, 2026, 12:12 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$FATE
Bullish
high confidence
Mentioned
$FATE
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$FATEBullishMed
01

Why it matters

The $15 M CIRM award reduces cash burn and signals external validation, potentially accelerating trial timelines and improving valuation multiples.

02

Market read

The funding announcement is a material corporate event for a micro‑cap biotech, likely to generate short‑term buying interest and set a positive tone for upcoming trial data.

03

What to watch

Future financing needs beyond Phase 2 and competitive CAR‑T programs could dilute the impact of this single grant.

Relevance 7/10Novelty 8/10Timing: same-day release

Background

Fate Therapeutics (NASDAQ:FATE) is a clinical‑stage biotech developing iPSC‑derived immunotherapies. The RECLAIM‑LN trial targets refractory lupus nephritis, a high‑unmet‑need indication.

Company-level read

Ticker impact

$FATEBullishHigh confidence
Context

Fate Therapeutics disclosed a $15 million CIRM CLIN2 grant to fund its Phase 2 RECLAIM‑LN trial of FT819 CAR‑T therapy for lupus nephritis.

Expected impact

likely upward pressure as the market prices in reduced financing risk and progress on a potentially registrational trial.

Evidence & confidence

Grant size ($15 M) is material for a micro‑cap biotech; funding directly supports a pivotal Phase 2 study, which can move the stock on trial‑related news.

Market effects

Sector

Strengthens the iPSC‑derived CAR‑T niche and may lift peers developing off‑the‑shelf cell therapies.

Regional

Highlights California’s regenerative‑medicine funding ecosystem, potentially encouraging further state‑backed grants.

Global

Adds to the pipeline of novel autoimmune therapies, a focus area for global biotech investors.

Counterpoint

What could challenge this read

The grant does not guarantee trial success; investors may remain cautious until data readouts.

Key entities

  • grantor
    California Institute for Regenerative Medicine (CIRM)

    State agency providing competitive funding for regenerative‑medicine projects.

  • product
    FT819

    Off‑the‑shelf CD19‑targeting CAR‑T cell candidate for lupus nephritis.

Read at source← All news

Related articles

AUG 14
$FATEMedAI 8/10

Fate Therapeutics, Inc.: Fate Therapeutics Initiates Potentially Registrational RECLAIM-LN Clinical Trial of FT819 for the Treatment of Lupus Nephritis

Fate Therapeutics (NASDAQ: FATE) dosed the first patient in its Phase 2 potentially registrational RECLAIM-LN trial of FT819 for refractory moderate-to-severe SLE with Class III or IV lupus nephritis. The single-arm study targets about 53 patients, with complete renal response at Week 26 as the primary endpoint. Enrollment is expected to finish in 15-18 months, by 1H2028.

finanznachrichten.de4 min
AUG 13
$FATEMed

Fate Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates

FATE THERAPEUTICS INC (FATE) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Fate Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates First lupus nephritis patient dosed in RECLAIM-LN, a Phase 2 potentially registrational trial utilizing FT819, an iPSC-derived, off-the-shelf CAR T-cell therapy; patient was treated

SEC EDGAR 8-K6 min
JUL 9
$FATEMedAI 8/10

Fate Therapeutics Receives FDA Clearance of Investigational New Drug Application for FT839 Product Candidate

Fate Therapeutics (NASDAQ: FATE) said the FDA cleared its IND for FT839, an off-the-shelf dual CAR T-cell candidate targeting CD19 and CD38. The company plans a Phase 1/2 multi-indication basket trial starting in 2H 2026 to test FT839 with standard-of-care for autoimmune diseases, with or without conditioning chemotherapy. Key initial indications include rheumatoid arthritis and lupus.

manilatimes.net3 min
JUL 6
$FATEMed

Fate Therapeutics to Present Preliminary Clinical Data of FT819 Off-the-Shelf CAR T-Cell Product Candidate for Systemic Sclerosis at the ISSCR 2026 Annual Meeting

Fate Therapeutics (NASDAQ: FATE) said it will present preliminary Phase 1 basket-trial data for its off-the-shelf CD19 CAR T-cell FT819 in systemic sclerosis at the ISSCR 2026 meeting (July 8–11). As of June 12, four patients showed rCRISS25+ and mean mRSS improvement at 3 months, with no CRS, ICANS, GvHD, hypogammaglobulinemia, or deaths reported.

manilatimes.net4 min